U.S. Markets close in 1 hr 36 mins

Pfizer’s Oncology Treatment Growth Drivers

Margaret Patrick
Pfizer’s Oncology Treatment Growth Drivers

Pfizer (PFE)’s Ibrance is the leading CDK4/6 (cyclin-dependent kinase 4/6) inhibitor drug in HR+ HER2- metastatic breast cancer indications.